Matches in SemOpenAlex for { <https://semopenalex.org/work/W1942153418> ?p ?o ?g. }
- W1942153418 endingPage "1110" @default.
- W1942153418 startingPage "1106" @default.
- W1942153418 abstract "Bendamustine is a multifunctional alkylating agent with single agent activity in myeloma. We designed the current phase 1/2 trial to determine the maximum tolerated doses (MTD) of bendamustine that can be safely combined with lenalidomide and dexamethasone and to assess the safety and efficacy of the combination. Patients with relapsed MM following at least 1 prior therapy, but no more than four lines of prior therapy and with measurable disease were enrolled. Bendamustine 75 mg/m 2 given on days 1 and 2, lenalidomide 25 mg given days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22, was the recommended Phase 2 dose. Seventy‐one patients were accrued: 21 on Phase 1 and 50 on Phase 2. The median age was 62.3 years; patients had a median of three prior lines of therapy (range 1–4), with over 70% of the patients having received prior lenalidomide, bortezomib, and/or peripheral blood stem cell transplant. Thirty‐four of 70 (49%) patients had a confirmed partial response or better, including 20 patients (29%) with a very good partial response or better. An additional 4 patients had a minor response, translating to an overall 55% clinical benefit rate. Grade 3 or higher toxicity was seen in 96% of patients, with ≥grade 3 hematologic in 94% and nonhematologic in 50%. The median progression free survival was 11.8 months and the median duration of response was 23 months. The combination of bendamustine, lenalidomide, and dexamethasone is very effective in relapsed multiple myeloma with high response rates and durable responses Am. J. Hematol. 90:1106–1110, 2015. © 2015 Wiley Periodicals, Inc." @default.
- W1942153418 created "2016-06-24" @default.
- W1942153418 creator A5012403700 @default.
- W1942153418 creator A5012884078 @default.
- W1942153418 creator A5026151069 @default.
- W1942153418 creator A5026574827 @default.
- W1942153418 creator A5033057342 @default.
- W1942153418 creator A5035985145 @default.
- W1942153418 creator A5037483577 @default.
- W1942153418 creator A5044733637 @default.
- W1942153418 creator A5046080795 @default.
- W1942153418 creator A5054336817 @default.
- W1942153418 creator A5063162231 @default.
- W1942153418 creator A5064538334 @default.
- W1942153418 creator A5088292582 @default.
- W1942153418 creator A5088590364 @default.
- W1942153418 creator A5091287816 @default.
- W1942153418 date "2015-10-06" @default.
- W1942153418 modified "2023-09-24" @default.
- W1942153418 title "Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma" @default.
- W1942153418 cites W1554061665 @default.
- W1942153418 cites W1965355458 @default.
- W1942153418 cites W1965428196 @default.
- W1942153418 cites W2012843756 @default.
- W1942153418 cites W2013370486 @default.
- W1942153418 cites W2034372485 @default.
- W1942153418 cites W2036200625 @default.
- W1942153418 cites W2044436186 @default.
- W1942153418 cites W2048579461 @default.
- W1942153418 cites W2056586434 @default.
- W1942153418 cites W2059895867 @default.
- W1942153418 cites W2066800926 @default.
- W1942153418 cites W2074533771 @default.
- W1942153418 cites W2096207943 @default.
- W1942153418 cites W2101576302 @default.
- W1942153418 cites W2110466835 @default.
- W1942153418 cites W2117172636 @default.
- W1942153418 cites W2120357104 @default.
- W1942153418 cites W2143756652 @default.
- W1942153418 cites W3189831118 @default.
- W1942153418 cites W4211114373 @default.
- W1942153418 doi "https://doi.org/10.1002/ajh.24181" @default.
- W1942153418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26331432" @default.
- W1942153418 hasPublicationYear "2015" @default.
- W1942153418 type Work @default.
- W1942153418 sameAs 1942153418 @default.
- W1942153418 citedByCount "20" @default.
- W1942153418 countsByYear W19421534182016 @default.
- W1942153418 countsByYear W19421534182017 @default.
- W1942153418 countsByYear W19421534182018 @default.
- W1942153418 countsByYear W19421534182020 @default.
- W1942153418 countsByYear W19421534182021 @default.
- W1942153418 countsByYear W19421534182022 @default.
- W1942153418 countsByYear W19421534182023 @default.
- W1942153418 crossrefType "journal-article" @default.
- W1942153418 hasAuthorship W1942153418A5012403700 @default.
- W1942153418 hasAuthorship W1942153418A5012884078 @default.
- W1942153418 hasAuthorship W1942153418A5026151069 @default.
- W1942153418 hasAuthorship W1942153418A5026574827 @default.
- W1942153418 hasAuthorship W1942153418A5033057342 @default.
- W1942153418 hasAuthorship W1942153418A5035985145 @default.
- W1942153418 hasAuthorship W1942153418A5037483577 @default.
- W1942153418 hasAuthorship W1942153418A5044733637 @default.
- W1942153418 hasAuthorship W1942153418A5046080795 @default.
- W1942153418 hasAuthorship W1942153418A5054336817 @default.
- W1942153418 hasAuthorship W1942153418A5063162231 @default.
- W1942153418 hasAuthorship W1942153418A5064538334 @default.
- W1942153418 hasAuthorship W1942153418A5088292582 @default.
- W1942153418 hasAuthorship W1942153418A5088590364 @default.
- W1942153418 hasAuthorship W1942153418A5091287816 @default.
- W1942153418 hasBestOaLocation W19421534181 @default.
- W1942153418 hasConcept C126322002 @default.
- W1942153418 hasConcept C141071460 @default.
- W1942153418 hasConcept C143998085 @default.
- W1942153418 hasConcept C2776063141 @default.
- W1942153418 hasConcept C2776364478 @default.
- W1942153418 hasConcept C2777478702 @default.
- W1942153418 hasConcept C2779338263 @default.
- W1942153418 hasConcept C2779609412 @default.
- W1942153418 hasConcept C2780401358 @default.
- W1942153418 hasConcept C2780653079 @default.
- W1942153418 hasConcept C2781442060 @default.
- W1942153418 hasConcept C29730261 @default.
- W1942153418 hasConcept C31760486 @default.
- W1942153418 hasConcept C71924100 @default.
- W1942153418 hasConcept C90924648 @default.
- W1942153418 hasConceptScore W1942153418C126322002 @default.
- W1942153418 hasConceptScore W1942153418C141071460 @default.
- W1942153418 hasConceptScore W1942153418C143998085 @default.
- W1942153418 hasConceptScore W1942153418C2776063141 @default.
- W1942153418 hasConceptScore W1942153418C2776364478 @default.
- W1942153418 hasConceptScore W1942153418C2777478702 @default.
- W1942153418 hasConceptScore W1942153418C2779338263 @default.
- W1942153418 hasConceptScore W1942153418C2779609412 @default.
- W1942153418 hasConceptScore W1942153418C2780401358 @default.
- W1942153418 hasConceptScore W1942153418C2780653079 @default.
- W1942153418 hasConceptScore W1942153418C2781442060 @default.
- W1942153418 hasConceptScore W1942153418C29730261 @default.